Clovis Oncology
CLVS
$0.08120
Share price
0.00%
Change (1 day)
-95.08%
Change (1 year)
Categories
Revenue for Clovis Oncology (CLVS)
Revenue in 2022 (TTM): $0.13 B
According to Clovis Oncology's latest financial reports the company's current revenue (TTM) is $0.13 B. In 2021 the company made a revenue of $0.14 B a decrease over the years 2020 revenue that were of $0.16 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Clovis Oncology from 2010 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | $0.13 B | -10.58% |
| 2021 | $0.14 B | -9.58% |
| 2020 | $0.16 B | 15.05% |
| 2019 | $0.14 B | 49.92% |
| 2018 | $95.38 M | 71.84% |
| 2017 | $55.51 M | 71067.95% |
| 2016 | $0.07 M | |
| 2015 | N/A | -100% |
| 2014 | $13.62 M | |
| 2013 | N/A | |
| 2012 | N/A | |
| 2011 | N/A | |
| 2010 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $93.02 B | 69,830.31% | 🇺🇸 USA |
 Pfizer PFE | $58.49 B | 43,875.76% | 🇺🇸 USA |
 AbbVie ABBV | $54.31 B | 40,734.15% | 🇺🇸 USA |
 Eli Lilly LLY | $34.12 B | 25,553.17% | 🇺🇸 USA |
 AstraZeneca AZN | $47.61 B | 35,692.09% | 🇬🇧 UK |
 BioMarin Pharmaceutical BMRN | $2.41 B | 1,718.68% | 🇺🇸 USA |